NuCana plc (NCNA) stock
NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.93−0.01 (-1.06%)
Close on Nov 12, 2026Market cap $3.87MP/E –Yield –
NuCana ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
NuCana's ebitda for the twelve months ending Dec 31, 2021 was -£46.96M. For fiscal 2025 it was -£19.84M. The highest annual figure on record is -£6.87M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -£19.84M | – |
| FY2024 | Dec 31, 2024 | -£22.29M | – |
| FY2023 | Dec 31, 2023 | -£32.21M | – |
| FY2022 | Dec 31, 2022 | -£38.39M | – |
| FY2021 | Dec 31, 2021 | -£46.96M | – |
| FY2020 | Dec 31, 2020 | -£35.53M | – |
| FY2019 | Dec 31, 2019 | -£25.98M | – |
| FY2018 | Dec 31, 2018 | -£18.76M | – |
| FY2017 | Dec 31, 2017 | -£25.50M | – |
| FY2016 | Dec 31, 2016 | -£8.35M | – |
| FY2015 | Dec 31, 2015 | -£6.87M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | -£15.47M | – |
| Q3 FY2021 | Sep 30, 2021 | -£9.75M | – |
| Q2 FY2021 | Jun 30, 2021 | -£10.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -£11.27M | – |
| Q4 FY2020 | Dec 31, 2020 | -£13.75M | – |
| Q3 FY2020 | Sep 30, 2020 | -£9.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -£7.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -£5.20M | – |
| Q4 FY2019 | Dec 31, 2019 | -£8.91M | – |
| Q3 FY2019 | Sep 30, 2019 | -£4.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -£5.70M | – |
| Q1 FY2019 | Mar 31, 2019 | -£6.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -£4.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -£3.49M | – |
| Q2 FY2018 | Jun 30, 2018 | -£2.86M | – |
| Q1 FY2018 | Mar 31, 2018 | -£7.42M | – |
| Q4 FY2017 | Dec 31, 2017 | -£5.80M | – |
| Q3 FY2017 | Sep 30, 2017 | -£14.23M | – |
See a number that looks wrong?